Antwerp Cardiovascular Center, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium.
EuroIntervention. 2021 Apr 2;16(18):e1511-e1517. doi: 10.4244/EIJ-D-19-00766.
Refractory angina is still a major public health problem. The coronary sinus Reducer (CSR) has recently been introduced as an alternative treatment to reduce symptoms in these patients. The aim of this study was to investigate objective improvements in effort tolerance and oxygen kinetics as assessed by cardiopulmonary exercise testing (CPET) in patients suffering from refractory angina undergoing CSR implantation.
In this multicentre prospective study, patients with chronic refractory angina undergoing CSR implantation were scheduled for CPET before the index procedure and at six-month follow-up. The main endpoints of this analysis were improvements in VO2 max and in VO2 at the anaerobic threshold (AT). Clinical events and improvements in symptoms were also recorded. A total of 37 patients formed the study population. The CSR implantation procedure was successful and without complications in all. At follow-up CPET, significant improvement in VO2 max (+0.97 ml/kg/min [+11.3%]; 12.2±3.6 ml/kg/min at baseline vs 13.2±3.7 ml/kg/min, p=0.026), and workload (+12.9 [+34%]; 68±28 W vs 81±49 W, p=0.05) were observed, with non-significant differences in VO2 at the AT (9.84±3.4 ml/kg/min vs 10.74±3.05 ml/kg/min, p=0.06). Canadian Cardiovascular Society (CCS) grade improved from a mean of 3.2±0.5 to 1.6±0.8 (p<0.01), and significant benefits in all Seattle Angina Questionnaire variables were shown.
In patients with obstructive coronary artery disease suffering from refractory angina, the implantation of a CSR was associated with objective improvement in exercise capacity and oxygen kinetics at CPET, suggesting a possible reduction of myocardial ischaemia.
难治性心绞痛仍然是一个主要的公共卫生问题。最近,冠状窦缩窄器(CSR)作为一种替代治疗方法被引入,以减轻这些患者的症状。本研究旨在通过心肺运动测试(CPET)评估接受 CSR 植入的难治性心绞痛患者的努力耐量和氧动力学的客观改善。
在这项多中心前瞻性研究中,接受 CSR 植入的慢性难治性心绞痛患者在索引手术前和 6 个月随访时进行 CPET。该分析的主要终点是 VO2 max 和无氧阈值(AT)时 VO2 的改善。还记录了临床事件和症状的改善。共有 37 例患者形成了研究人群。CSR 植入程序在所有患者中均成功且无并发症。在随访 CPET 时,VO2 max(+0.97 ml/kg/min[+11.3%];基线时为 12.2±3.6 ml/kg/min,随访时为 13.2±3.7 ml/kg/min,p=0.026)和工作量(+12.9[+34%];68±28 W 至 81±49 W,p=0.05)均有显著改善,而 AT 时 VO2 无显著差异(9.84±3.4 ml/kg/min 至 10.74±3.05 ml/kg/min,p=0.06)。加拿大心血管学会(CCS)分级从平均 3.2±0.5 改善至 1.6±0.8(p<0.01),西雅图心绞痛问卷的所有变量均显示出显著改善。
在患有阻塞性冠状动脉疾病且患有难治性心绞痛的患者中,植入 CSR 与 CPET 时运动能力和氧动力学的客观改善相关,提示心肌缺血可能减少。